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The feasibility of placing prosthetic grafts within 
the arterial tree by inserting them via a remote site, 
guiding them intraluminally to the appropriate 
location, and fixing them there with attachment 
systems, such as a variety of expandable stems, has 
been demonstrated in animals and human beings. >a 
There is a potential for these transluminally placed 
endovascular g afts (TPEGs) a to provide improved 
treatment for a variety of arterial esions, including 
aneurysms, traumatic injuries, and arteriosclerotic 
occlusions, and TPEG repairs of all three kinds of 
lesions have been carried out at various levels of the 
arterial tree with short-term success. 1'4-17 Because 
TPEG repairs can be performed less invasively, their 
~See appendix. 
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aAt present, these include a variety of graft-stent combinations. 
However, these guidelines apply to other devices that will have or 
develop blood impervious walls and that may be inserted via 
intraluminal routes to provide prosthetic support or replacement 
of a diseased arterial wall. Devices that involve autologous tissue 
(e.g., stents and a vein graft) are also a variety of TPEG. Another 
variety is TPEGs used in the systemic or portal venous ystems. 
Although some generalities in these guidelines apply to these 
autologous and venous TPEGs, they will not be dealt with 
specifically in this document. Throughout hese guidelines the 
terms TPEG, stentedgraft, andstentgraft re used interchangeably, 
although it is recognized that TPEG has a broader meaning 
because not all of these devices will necessarily include a stent 
component per se. 
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risks mad costs may be less than those of standard 
vascular graft operations. They will therefore be 
extremely attractive to both patients and physicians, 
and consequently there will be enormous pressure to 
develop and use these devices rapidly. 
The purpose of this document is to foster the 
development of safe, effective devices for performing 
TPEG repairs of various arterial lesions at all levels of 
the arterial tree. To this end, it will provide guidelines 
for the careful and structured evaluation and moni- 
toring that are necessary to document the safety, 
efficacy, and effectiveness b of these devices in various 
settings before they undergo widespread clinical use. 
Although these guidelines are not a regulatory 
document, hey are intended to help avoid premature 
and potentially harmful usage of TPEGs. 
GENERALITIES 
Types of TPEGs 
TPEGs can be divided into those that are covered 
single stent devices' and end fixation devices, which  
bSaftty is defined as freedom from complications or intrinsic device 
failure; efficacy is defined as the ability of the device to restore the 
vascular wall and luminal integrity, to prevent aneurysm expansion 
and rupture, or to maintain luminal patency; and effectiveness is 
defined as the ability to extend patient survival and limb or organ 
function by preventing aneurysm expansion and rupture or by 
maintaining arterial flow through the diseased segment of the 
artery. 
CA covered single stent is one to which a prosthetic graft, which is 
or will become impervious to blood, if fixed so that the graft covers 
a portion or all of the internal or external surface of the stent after 
its expansion within a blood vessel. Some devices of this variety may 
incorporate stentlike components within a graft matrix to provide 
an integrated unit: others may consist ofa stent alone that becomes 
impervious to blood. 
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comprise a prosthetic graft fixed with a stent or 
other attachment system at both ends. Variants of 
the latter are bifurcated ¥ grafts or branched 
grafts with attachment devices at all three ends and 
long grafts stented at one end and with no stent 
or a suture anastomosis at the other end. Further 
division of TPEGs can be based on the characteristics 
of the device, specifically the nature of the delivery 
system (e.g., sheath/no sheath, over a wire/not over 
a wire, etc.), the nature of the attachment orfixation 
system and method (balloon-expandable, spring- 
expandable, or mechanically expandable stent or 
other device, with or without hooks for fixation to 
the vessel wall, and the nature ofthegraft or covering 
material component (knitted polyester [Dacron], d 
woven polyester [Dacron], d polytetrafluoroethy- 
lene [PTFE] or other developmental prosthetic ma- 
terial). 
Usage categories 
Because different characteristics and properties of 
TPEGs may be required to treat different forms of 
arterial disease in different parts of the arterial tree, 
usage must be defined on the basis of lesion location 
and lesion pathology. Safety, efficacy, and effectiveness 
must at least be considered separately for each device 
and each usage. This document provides guidelines 
for evaluating TPEGs according to usage categories 
defined by the following vessel sizes and locations: 
the thoracic and suprarenal aorta, large arteries (in- 
frarenal aorta, iliac, innominate, common carotid 
and subclavian), and medium-sized arteries (femoral, 
popliteal, axiUary, visceral, renal, coronary, e verte- 
bral, e and carotid bifurcation and branches ); and for 
devices to be used to treat aneurysms, traumatic lesions 
(false aneurysms, arteriovenous fi tulas, mural inju- 
ries), stenotic and occlusive l sions, and dissections and 
intramural hematomas. 
Usage categories other than these may be re- 
quired on the basis of pathologic, anatomic, or 
physiologic haracteristics of the patient or lesion 
being treated. For example, some aneurysmal, trau- 
matic, or ulcerating atherosclerotic lesions may cause 
distal embolization as their only manifestation. The 
suitability of such lesions for TPEG treatment might 
need to be evaluated separately. 
For purposes of demonstrating safety, efficacy, 
and effectiveness, each specific device should be 
considered for evaluation i a specified-sized artery in 
one or more locations with similar defined isease. 
However, it is possible that a given device will be safe 
and effective in several different sized arteries, in 
different locations, and even for the treatment of 
different ypes of lesions. Accordingly, it will be 
acceptable to evaluate and demonstrate safety, effi- 
cacy, and effectiveness of a given device by studies in 
which that device is used in more than one location 
or for more than one type of lesion. In such 
circumstances a satisfactory ationale and justification 
for combining usage categories must be provided. All 
studies hould be designed to demonstrate statisti- 
cally valid conclusions within one or more subdivi- 
sions of this categorization system. 
Requirements for developmental nd 
testing centers 
Because TPEGs require vascular surgical skills 
and catheter-guidewire-imaging skillsto insert and 
deploy, the clinical teams involved in their develop- 
ment and initial testing in patients hould consist of 
individuals with the highest levels of expertise inboth 
of these modalities, f This means that individuals 
possessing skills and experience in vascular surgeryg 
and interventional r diology must be involved in and 
responsible for the efforts of these developmental 
centers. Usually this combination ofskills will require 
two or more individuals, avascular surgeon and an 
interventional radiologist who work smoothly to- 
gether as a team, although it is possible that one 
individual will possess the requisite skills and expe- 
rience to perform all parts of the procedure. It is 
recommended that developmental or research centers 
testing these devices be staffed by integrated teams of 
vascular surgeons and radiologists, coordinated by a 
single individual who is familiar with vascular disease 
and natural history and all standard treatment alter- 
natives and who bears overall patient responsibility. 
To deal optimally with unexpected problems, proce- 
dDacron is a trademark of DuPont Co., Inc., Wilmington, Del. It 
refers to the polyester, polyethyleneterephthalate. Throughout 
these guidelines the generic term, polyester, will be used for this 
material. 
°Coronary, carotid, and vertebral devices will have special prob- 
lems relating to the end organs they supply and technical challenges 
to  obtain access. Appropriate monitoring of end organ function, 
that is, the heart or brain, will be required with devices used in 
these arteries. 
~Separate training and credentialing guideline documents for indi- 
viduals who can perform vascular surgery and endovascular p oce- 
dures have been prepared by various pecialty organizations. 18-23 
The general principles expressed in these documents should also 
apply to this guideline document. 
gProcedures performed for lesions of the thoracic aorta may require 
the participation of individuals skilled and credentialed in cardio- 
thoracic surgery, especially if it appears that cardiopulmonary 
bypass may be necessary to manage device complications. 
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dures carried out on patients hould be performed in
a procedural room that is equipped with digital 
imaging fluoroscopy and that has all the appropriate 
equipment and personnel to carry out open arterial 
operations. In light of current designs, approaches, 
and clinical experience and because the possibility 
that large artery injury, occlusion, or rupture may 
require immediate emergency operation, procedures 
conducted on the thoracic or abdominal aorta, the 
iliac arteries, or other aortic branches hould be 
performed in a room that has appropriate imaging 
devices and equipment and staff to carry out emer- 
gency major vascular or cardiovascular surgery. (See 
the section on "Requirements For Facilities in Which 
TPEGs Will Be Used Clinically" for further details 
regarding equipment requirements.) 
In addition, these centers hould have inpatient 
radiologic and vascular surgical services experienced 
in performing the full range of standard arteriogra- 
phy, catheter-directed angioplasty and stent place- 
ment, and all vascular and cardiothoracic operations. 
They should also have the outpatient facilities, 
noninvasive vascular diagnostic laboratories, radiol- 
ogy services, and support staffs to perform the 
high-quality imaging techniques needed for accurate 
and thorough patient follow-up evaluation. Centers 
involved in these studies must demonstrate a com- 
mitment to long-term follow-up. 
Comparison between TPEGs and standard 
arterial grafts and stents 
It should be recognized that some properties of 
TPEGs may differ from those required of standard 
grafts or stents used to treat similar lesions in similar 
locations. Because TPEGs will be inserted from a 
remote site and guided into position, there are clear 
advantages to reducing their unexpanded cross- 
sectional diameter or "profile" as much as possible. 
In this way the requirement that they be introduced 
through an open arteriotomy in a large-caliber 
artery will be minimized. Thus devices with a low 
profile offer clear advantages in terms of feasibility 
and applicability. However, making the TPEG thin 
and flexible to achieve a low, unexpanded pro- 
file may require a thinner graft with reduced 
strength. 
Currently it is not known whether TPEGs need 
the same burst strength or porosity characteristics as a 
standard arterial graft. A TPEG that will be placed 
within the unsupported lumen of an aortic aneurysm 
must have adequate strength and durability to with- 
stand aortic pressures and flows, although itmay not 
have to mcet he same safety factors required ofstan- 
dard aortic grafts with regard to these parameters. In 
addition, aTPEG intended for use in the treatment of
unruptured aneurysms may not require the same po- 
rosity specifications as a standard graft used to treat 
the same condition. Because the endoluminally in- 
serted evice will be contained within the intact aneu- 
rysm sac, greater porosity may be tolerable because 
transinterstitial bleeding will be contained by the an- 
eurysm wall until fibrin deposition occludes the 
pores. Moreover, aTPEG placed within a stenotic or 
occluded artery may receive structural support from 
the surrounding arterial wall, thereby allowing the 
use of grafts with different physical properties (e.g., 
decreased wall thickness and strength). Long-term 
experimental and clinical studies will be required to 
settle these issues. In contrast, some endoluminally 
placed grafts may require unusual characteristics not 
needed with standard grafts. Examples include physi- 
cal properties that contribute to an intact and fixed 
friction seal at junction points with host arteries, to 
developing rapid and secure impermeability to blood 
in ruptured aneurysms and traumatic arteriovenous 
fistulas, or to resisting compression when a TPEG is 
placed within occluded arteries. 
DEVELOPMENTAL STUDY PROTOCOLS 
When TPEGs and appropriate systems for their 
insertion are developed and are believed to be 
suitable for treatment of specific lesions in specified 
locations, the following general guidelines are rec- 
ommended for preclinical and clinical testing before 
the devices are brought into widespread usage. For 
any device, the evaluation must consist of four 
phases: bench testing, (structural/mechanical), pre-
clinical (animal) testing, clinical testing-feasibility, 
and clinical testing-comparative performance. How- 
ever, in identifying appropriate testing for any 
device, consideration must be given to the mode(s) 
of failure and its/their effect on the performance of
the device. 
Bench testing 
For the graft portion of the device, this should 
consist of essentially the same tests of physical 
properties, uch as strength, durability, porosity, kink 
resistance, suture holding ability, h flexibility, and 
longitudinal nd radial stretchability, asare required 
for a currently standard or proposed new arterial 
prosthesis. 2426 The possibility also exists that modi- 
fied requirements may need to be developed for new 
graft materials that may be developed and used for 
alf an open surgical anastomosis may be required at one end. 
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TPEGs. In addition, the stent portion or attachment 
system of a TPEG device will have to be evaluated for 
the various characteristics mportant to its function, 
such as inermess in blood, lack of toxicity, absence of 
metal fatigue, flexibility, compression resistance, and 
other physical properties that contribute to a leak- 
proof seal and secure fixation at junction points with 
arteries. 27 Finally, the delivery system of a device will 
require bench testing to demonstrate appropriate 
maneuverability, kink resistance, radiopacity, and 
marker visibility to be effective in the clinical setting 
in which it will be used. 
Animal testing 
Successful animal implantation of all TPEG 
devices, by use of the same introduction systems and 
localization and deployment methods that will be 
used in patients, should be required before clinical 
trials can be undertaken. Successful implantation 
includes the ability to visualize and deploy the device 
by techniques similar to those that will be required in 
patients; the firm fixation of the device at the site of 
original implantation; and acceptable freedom from 
leakage, migration, vessel wall erosion, thrombosis, 
excessive intimal hyperplasia with luminal narrow- 
ing, and distal embolization. There should also be 
acceptable freedom from other complications related 
to the fixation component or stent, particularly those 
with hooks or spikes. The duration of observation i
animal testing should be for a minimum of 6 months 
before clinical tests can be undertaken. Longer 
studies may be needed if synthetic materials not 
currently in use in the vascular system are involved. 
The TPEG should be inserted in animal models at 
similar although not necessarily identical anatomic 
locations to those intended for use in patients. Every 
effort should be made to use animal models that 
mimic as closely as possible the clinical problem being 
addressed. Device insertion techniques and end- 
points studied should parallel those that will apply in 
the clinical setting as much as possible. Imaging 
techniques, such as angiography or intravascular 
ultrasonography (IVUS), that provide visualization 
and localization of the fixation device and the graft are 
important parameters to evaluate in these studies. 
It is recognized, however, that animal models 
have several limitations in evaluating TPEGs. First, 
the commonly available large animal models (dogs, 
pigs, or sheep) have arteries that are smaller than 
comparable arteries in human beings. Calves are 
larger, and their arteries better approximate he size 
of human arteries, but their rapid growth limits their 
utility for anything other than short-term studies. 
Second, it is not possible to produce in animals 
arterial lesions that are comparable to those in 
patients, with the possible exceptions of traumatic 
arteriovenous fistulas, false aneurysms, and aortic 
dissections. 28 Although animal models with fusiform 
polyester cloth aneurysms have been described 2'3'29'3° 
and have some limited applicability, good models of 
true aneurysms and arteriosclerotic o clusive disease 
do not exist. Accordingly, animal studies have limited 
applicability in predicting the outcome of TPEGs in 
treating some human arterial lesions. Furthermore, it 
may be necessary to test some devices in more than 
one animal model to address all concerns (e.g., 
long-term implants in dogs with acute studies in 
calves to study clinical-sized devices). All animal 
studies hould include gross and histologic evaluation 
and, if possible, angiographic evaluation, computed 
tomography (CT) scanning with contrast, magnetic 
resonance imaging (MRI), and/or IVUS to docu- 
ment device, luminal, and arterial wall structure and 
relationships. 
All the animals involved in these studies must 
receive humane care in compliance with the "Prin- 
ciples of Laboratory Animal Care" formulated by the 
National Society for Medical Research and the Guide 
for the Care and Use of Laboratory Animals (NIH 
Publication No. 86-23, revised 1985) prepared by 
the National Academy of Sciences. 
Clinical testing 
Clinical testing must demonstrate the safety, 
efficacy, and effectiveness of TPEGs in the treatment 
of human arterial diseases. Separate studies may be 
needed for each usage category and each artery size 
and lesion described in the "Generalities" ection. 
However, it is possible that some devices will be 
suitable for treating multiple categories of lesions. 
Therefore it may be appropriate to combine lesion 
sites and pathologic ategories for clinical testing 
when this can be supported and justified. This is 
particularly likely when treatment of uncommon 
lesions is being considered. Clinical testing will be 
divided into two phases: feasibility testing and 
comparative performance t sting. 
Feasibility testing. This should demonstrate that 
insertion of a TPEG device is possible in a given 
disease state in a given location and that the device 
functions afely and effectively for at least 6 months. 
These tests must include comparative preprocedural 
and postprocedural noninvasive measurements of the 
distal circulation and, in the case of aneurysms, their 
size before and 3 and 6 months after TPEG place- 
ment. These measurements include lower extremity 
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segmental systolic pressures and pulse volume re- 
comings (or Doppler waveform easurements) and 
ultrasound, contrast-enhanced CT scanning, MRI, 
and/or IVUS measurements of aneurysm size) They 
must be available in at least lOpatients and should be 
supplemented by appropriate imaging studies to 
demonstrate d vice patency, confinement offlowing 
blood to the graft lumen, and freedom from leakage, 
migration, and aneurysm enlargement) Preplace- 
ment, completion, and 6 months postplacement ar e- 
riographic onfirmation should be provided in at 
least one half of the patients and preferably in all. 
However, if other less invasive modalities can provide 
accurate equivalent information, arteriographic study 
may be unnecessary. 
There are two types of feasibility studies. In both, 
protocols should be consistent with Institutional 
Review Board (IRB) and Food and Drug Adminis- 
tration (FDA) standards and regulations. 
In the first type of feasibility study, standard usage, 
the TPEG treatment is offered to patients who are 
candidates for standard operative abdominal aneu- 
rysm repair, 2s standard operative graft or balloon 
angioplasty/stent treatment of occlusive lesions, or 
standard surgical repair of traumatic lesions or 
peripheral neurysms for the usual indications. In this 
setting, the patient must be prepared for and willing 
to undergo the standard procedure if the TPEG 
placement is impossible or unsuccessful or has a 
complication. In general, if the aorta or iliac arteries 
are involved or if limb salvage is the indication, 
patients having these initial TPEG procedures should 
have them performed in a location that is equipped 
and staffed for emergency operative repair. 
In the second form of feasibility study, high-risk 
usage, patients who are unsuitable for or at high risk 
for the standard treatment may be offered the new 
TPEG treatment as an option, k In the case of 
abdominal aneurysm repair, these can be patients 
with large, threatening aneurysms whose operative 
risk is excessive, for example, in excess of 3 to 4 times 
iThese measurements should permit accurate definition of wall, 
clot, and lumen (flowing blood) dimensions. 
iln the descending thoracic aorta, transesophageal echo may be 
useful for these evaluations. 
kThere is some disagreement over the ethical merits of demon- 
strafing feasibility in patients for whom no surgical rescue 
procedure is available if the untested evice fails. These guidelines 
cannot resolve this disagreement. Ideally, some prior experience or 
other evidence should be available to suggest feasibility before 
high-risk usage of a new "['PEG device is undertaken. High-risk 
usage protocols must have risk factors or criteria clearly defined and 
objectively documented to avoid overly liberal use. 
normal, on the basis of heart, lung, or liver disease or 
previous abdominal scarring or infection? 1 In the 
case of occlusive lesions or peripheral neurysms, the 
same risk factors and the presence of limb- 
threatening ischemia or a large aneurysm could be 
considered an indication to offer TPEG placement as
a therapeutic option. 
Comparative performance testing-clinical 
trials. This phase of evaluation is designed to show 
that the TPEG device will perform essentially equiva- 
lent to or significantly better than standard treatment. 
There are several ways to test safety, efficacy, and 
effectiveness and to show equivalence orsuperiority. 
It is not the purpose of this document to specify how 
a clinical trial of a new TPEG device should be 
designed and conducted. This has been discussed in 
a recent editorial. 32 However, such trials should be 
conducted in a fashion that is scientifically sound and 
that provides tatistically valid data relating to the 
important criteria to be described below for the 
various usage categories. When it is feasible and 
appropriate, these studies should be designed to 
permit a valid comparison of the safety, efficacy, and 
effectiveness of a new TPEG device and current 
standard treatment(s) of similar arterial esions in 
similar patients. In other circumstances, when it may 
not be feasible or in the interests of patients to obtain 
such valid comparative performance data the clinical 
trial study protocol should clearly indicate the reasons 
for this and provide an acceptable alternative method 
for testing the hypotheses posed in the study and 
documenting the new TPEG device's afety, efficacy, 
and effectiveness) 
Those responsible for the clinical trials of new 
TPEG devices hould consult he appropriate office 
at the FDA (Office of Device Evaluation) before the 
design and conduct of a trial. By doing so, the 
investigator will become familiar with the FDA's 
requirements and recommendations for premarket 
approval of a new medical device and how to design 
an appropriate trial that is likely to yield valid 
conclusions about the clinical performance of the 
TPEG device. 
In general, the format recommended throughout 
iln some exceptional circumstances in which no satisfactory 
treatment exists, a high-risk usage study of a TPEG device may 
constitute appropriate vidence for the manufacturer to obtain 
approval to market and sell the devicc for a specific indication. An 
example would be use of a TPEG device in the treatment of a 
central arteriovenous fistula or false aneurysm in patients who 
would otherwise require a thoracotomy or laparotomy for 
standard surgical repair and in whom intercurrent heart or lung 
disease precludes general anesthesia or makes its risk prohibitive. 
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these guidelines will entail a feasibility study of at least 
10 patients observed for 6 months, followed by a 
comparative p rformance study with an adequate num- 
ber of patients in the device test group monitored 
after the procedure to allow statistically valid com- 
parisons after 1 to 2 years with similar patients with 
similar stages of the disease process. TM Comparative 
performance studies should include the primary 
criteria listed in Table I with regard to procedural (30 
day) morbidity and mortality rates and 1 to 2 year 
device safety and efficacy. The results should allow 
statistically valid and biologically meaningful conclu- 
sions indicating whether a given device provides 
results that are better than, worse than, or equivalent 
to standard treatment as measured by these criteria. 
Demonstration f statistically significant equivalence 
between two treatment groups may require unac- 
ceptably large numbers of patients o that compara- 
tive studies hould be designed to show statistically 
significant differences between the TPEG and stan- 
dard treatment or essential equivalence, that is, no 
grossly apparent difference. 
Every effort must be made in all clinical stages of 
testing to obtain postmortem examination fpatients 
who die of any cause to determine the cause of death 
and to perform acomplete xplant analysis including 
gross and microscopic examination ofthe device and 
the sites of device implantation and fixation to 
determine the structure and histologic ondition of 
the proximal and distal vessel and of the aneurysm or 
other arterial lesion being treated. 
It is recognized that some comparative perfor- 
mance trials may, when appropriately justified, evalu- 
ate a specific TPEG device in more than one location 
or for treatment of more than one type of lesion. 
However, because device requirements for different 
lesions and different locations may vary, the crucial 
data to be collected or criteria for seven distinct major 
types of trials are described separately in Table I and 
the following text sections. These seven major types 
of trials are (1) infrarenal aortic aneurysms (tubular 
device required); (2) infrarenal ortic aneurysms with 
no distal neck or with lilac aneurysms (bifurcated 
device required); (3) peripheral neurysms (femoral, 
popliteal, or other); (4) traumatic arterial esions 
(false aneurysms, arteriovenous fistulas, or mural 
injuries); (5) iliac artery (common and external) 
occlusive disease with or without involvement ofthe 
distal aorta; (6) femoral or popliteal artery occlusive 
disease; and (7) descending thoracic aortic disease 
(aneurysms, dissections, and traumatic injuries). 
Other data that should be collected and analyzed in 
addition to those listed in Table I are duration of the 
procedure, time in an intensive care unit, length of 
hospital stay, and the number of units of homologous 
blood transfused. Systemic omplications of these 
procedures (defined in Table IIA) and device-related 
failures or complications (defined in Table IIB) must 
also be documented and analyzed. 
It is possible that other types of clinical trials will 
be required in other settings or with specific sub- 
groups of patients. These other trials can be based on 
the seven major types of trials described below. 
Abdominal aortic aneurysm 
(infrarenal) - tubular devices 
Adequate data must be collected so that, after a 
group of patients ~are treated by the TPEG device 
and compared with standard operative repair with a 
prosthetic graft, it can be determined that the groups 
being compared are similar except for the form of 
treatment. 
Preprocedural data should be collected on age, 
sex, ethnic origin, height, weight, diabetic status, 
cardiac function and risk factors, pulmonary func- 
tion and risk factors, hepatic and renal fimction, he- 
matologic values, lower extremity pulse status and 
ankle/brachial indexes (ABI), and previous abdomi- 
nal operations and scars (Table III). CT scanning, 
MRI, ultrasonography, and/or arteriography should 
be performed and data acquired with regard to 
aneurysm length, transverse, and anteroposterior 
diameters; the extent and dimensions of intraluminal 
clot and flowing blood; the diameter, length, and 
degree of calcification of the normal infrarenal aortic 
segment (i.e., the proximal and distal aortic "neck" or 
"cuff'); the diameter and tortuosity of the common 
and external iliac arteries (supplement with diagram); 
and the location and relationship to the aneurysm of 
patent renal arteries, lumbar arteries, and the superior 
and inferior mesenteric arteries. These data may be 
supplemented by MRI or CT three-dimensional aor- 
tic reconstructions showing aneurysm, neck, and 
branch structure, including a definition of the areas 
occupied by intraluminal c ot and flowing blood. 
Intraprocedural data should be collected regarding 
mlt is recognized that standard treatment group parameters may 
best be represented by a range of reported values. TPEG and 
standard treatment groups of patients must have equivalent 
systemic risk factors and disease morphology and complexity. 
°Patient selection criteria will be based on device characteristics. 
However, all patients must be suitable candidates for standard 
operative repair of their aneurysm and must have appropriate 
indications for such a repair. 
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Table I. Important study criteria for each category of arterial lesion/location 
Infrarenal 
AAA with 
Infrarenal i l iac Peripheral 
AAA aneurysm aneurysm Traumatic Aortoiliac Femoropopliteal 
Study tubular bifurcated tubular arterial occlusive occlusive 
criteria device device device lesions disease disease 
Descending 
thoracic 
aorta 
Procedura l  death + + + + + + + + + + 
Compl icat ions  ~ 
Myocard ia l  infarct ion + + + + + + + + + + + + 
Other  cardiac + + + + + + + + + + + + 
Pu lmonary  + + + + + . + + + + + + + 
Renal  failure + + + + + + + + + + + + 
Bowel  ischemia + + + + - - + + - + + 
Bowel  obst ruct ion  + + + + - - + + - - 
P rocedura l  failureP + + + + + + + 
Leak ++ ++ ++ ++ ++ ++ ++ 
Device migrat ion  + + + + + + + + + + + + + + 
Embol i sm + + + + + + + + + + + + + + 
Thrombos is  + + + + + + + + + + + + + + 
Inadequate  funct ions  + + + + + + + + + + + + + + 
L imb loss + + + + + + + + + + + 
Paraplegia or  paraparesis + + . . . .  + + 
Other§  + + + + + + + + + 
Death  f rom rupture  + + + + - + + + + - + + 
Convers ion  to s tandard  + + + + + + + + + + + + + + 
open operat ion  
Increase in aneurysm + + + + + + + - - + + 
size 
Lack o f  increase in aneu- + + + + + + - - - + + 
rysm size 
Graft  patency + + + + + + + + + + + + + + 
Graft  en largement  ( > 25%)  + + + + + + + - + + 
Persistent f low in sac or  + + + + + + + + + + 
branch artery 
Normal  f low w i thout  + + + + + + + + + + + + + + 
leak, twist, or  mi-  
g rat ion  
AAA,  Abdomina l  aort ic aneurysm;  + +,  pr imary  cr iter ion; + ,  secondary  cr iter ion; - ,  recorded but  probab ly  not  relevant. 
~Definit ions prov ided in Table II. 
Hnab i l i ty  to insert device. 
~F low reduct ion  w i thout  thrombos is .  
§ Infect ion,  bleeding. Infect ion involv ing an endo lumina l  device is + + in all categories. 
the site of device placement, including that of the 
proximal and distal attachment, if appropriate, rela- 
tive to the aorta/aneurysm; the relationship of the 
device, its stented and unstented portions, and its 
covered and uncovered portions to patent arteries; 
and the diameter and length of the stent(s) (when 
applicable) after deployment. Data should also in- 
clude the length and diameter of the graft, the site and 
route of introduction, sheath configuration and 
diameters, blood loss, total fluoroscopy time, he- 
matoma formation, and any problems associated 
with device insertion. 
If balloons or stents other than those designated 
in the experimental protocol are used, the length, 
diameter, specifications, and manufacturer should be 
recorded along with inflation volume, time, and 
pressure. ° Data on any associated procedure that is 
required, such as transluminal balloon angioplasty of 
the lilac arteries, placement of additional stents,V 
covered stents,P stented grafts,V or arterial repair or 
thrombectomy should also be recorded. The type of 
anesthesia, medications required, the duration of the 
°A standard ized el ivery system should  be used w i th  each device 
being s tud ied  for  a part icular  lesion in a part icular  location. 
Otherwise,  stratif ication based on  delivery system var iat ion will be 
required.  However ,  o ther  bal loons and  mater ia l  may be required 
dur ing  the implantat ion  procedure  or  for  management  or treat- 
ment  o f  compl icat ions,  and  all such details shou ld  be recorded.  
PIf these are invest igat ional  devices, their  use could confuse the 
results o f  a TPEG trial. Such use o f  adjtmctive invest igat ional  
devices shou ld  be identif ied and  results wi th  them reported 
separately f rom other  results obta ined w i thout  them. 
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Table IIA. Definitions of systemic or organ-related complications 
Complication Definition 
Myocardial infarction 
Other cardiac complication 
Arrhythmia 
Congestive heart failure 
Pulmonary complication 
Renal failure 
Bowel ischemia 
Bowel obstruction 
Neurologic omplications 
Stroke 
Transient ischemic attack 
Paraplegia or paraparesis 
Limb loss 
Significant elevation of CPK-MB, appearance of new significant Q 
wave or loss of R waves 
Requiting treatment with drugs, cardioversion or pacemaker 
Requiring tracheal intubation or ICU care 
Requiting tracheal reintubation, extension fventilator support be- 
yond 48 hours, ICU care beyond 3 days or return to ICU 
Creatinine rise > 30% or requiring dialysis 
Mucosal hemorrhage or requiring bowel resection orcolostomy 
Requiring extended ( > 4 days) nasogastric intubation orlaparotomy 
New neurologic event lasting > 24 hours 
Neurologic event lasting < 24 hours 
Lasting > 24 hours 
Major amputation at level of ankle or above 
CPK-MB, Creatinine phosphokinase myocardial band; ICU, intensive care unit. 
procedure, and a description or diagram of the 
procedure should be recorded, and a hard copy of the 
completion arteriogram should be kept on file. 
Any procedural complications uch as device 
twisting, leakage, misplacement, migration, or failure 
should be recorded along with the endovascular o  
operative maneuvers required to manage the com- 
plication. If device removal is required, the steps 
involved should be detailed along with the outcome 
of these corrective fforts. Complications involving 
the native arterial tree and their management should 
also be documented. 
Early postprocedural data (7 to 10 days) should 
include the duration of hospitalization, a description 
of wound healing, an evaluation of device position, 
luminal patency, and complications (e.g., leakage, 
migration, kinking, twisting, or obstruction). These 
device-related valuations should be based on con- 
ventional radiographic, CT, MRI, IVUS, or color- 
flow duplex imaging studies. Further evaluation by 
arteriography may be needed to exclude or further 
assess leakage, and ultrasonography may be used to 
demonstrate shrinkage and pulsatility of the aneu- 
rysm wall. 
Complications from the procedure or the device 
should be described along with the steps taken to 
manage these complications and the outcome. Dur- 
ing this early postprocedural period, all preproce- 
dural data relative to renal and hematologic function, 
noninvasive valuation of the peripheral circulation, 
aneurysm, and aortic structure should be repeated. 
This will permit an assessment of early device safety 
and efficacy. 
Early mid term (6 months) postprocedural data 
should include all those parameters evaluated in the 
first 7 to 10 days after device insertion and must 
include at least one adequate imaging technique (CT, 
IVUS, MRI, duplex ultrasonography, or arteriogra- 
phy) to evaluate luminal patency, device integrity and 
localization, aneurysm size and pulsatility, and free- 
dom from leakage. All these parameters plus a 
hematologic and biochemical evaluation of organ 
function should be studied approximately 6 months 
after device insertion, although it is understood that 
many of these tests, particularly those that can be 
performed noninvasively or by blood sampling may 
be performed at more frequent intervals, specifically 
between 2 to 3 months after device insertion. 
Late midterm (1 year) postprocedural data, includ- 
ing all those parameters outlined for early midterm 
evaluation, should be collected I year after device 
insertion. If a new device is as effective and as safe as 
standard operative aneurysm repair, according to the 
primary criteria in Table I, for 1 year, the manufac- 
turer of that device may seek clearance to market and 
sell it for specific indications? 5 
The same data including adequate imaging 
should be collected at 6- to 12-month intervals 
thereafter for the life of all patients receiving these 
devices. In that way, a determination can be made of 
long-term or late postprocedural (3 to 5 years) safety, 
efficacy, and effectiveness; and comparative perfor- 
mance of the device in relationship to standard 
aneurysm repair can be determined. With this 
information and the data regarding adverse device 
effects, it will be possible to determine whether the 
TPEG device should be used as preferential treatment 
for selected patients at high risk, for patients now 
subjected to standard surgical repair, or even for 
some smaller aneurysms not currently being treated. 
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Table  l iB .  Definition of  device failures or complications 
Complication Definition 
Device occlusion 
Stenosis 
Leak 
Migration 
Embolism 
Absence of flow through the device with or without intraluminal 
thrombosis 
Device related lumen reduction in, proximal to, or distal to the de- 
vice associated with a reduction in flow or pressure 
Flow of blood outside the lumen of a device when all such flows should 
be contained within its lumen 
Displacement of the device sufficient to be associated with another 
complication, e.g., occlusion, stenosis or leak 
Formation of thrombosis within the device with migration to a distal 
artery 
Table I I I .  Prerequisite information regarding risk factors 
Cardiac function 
Renal function 
Pulmonary function 
Hematological profile 
Liver function 
Local risk factors 
Left ventricular ejection fraction 
History of myocardial infarction 
Presence of significant Q waves 
Arrhythmias 
Thallium persantine stress test abnormalities 
History of angina pectoris 
History of congestive failure 
History of diastolic blood pressure > 90 mm Fig or systolic pressure 
> 160 mm Hg 
History of diabetes 
Serum BUN 
Serum Creatinine 
Arterial blood gases on room air 
FEV 1 
Chest radiogram abnormalities 
Decreased exercise tolerance 
CBC, platelet count, prothrombin time, partial thromboplastin ime 
Serum albumin, bilirubin, SGOT, SGPT 
Prothrombin time 
History of cirrhosis, hepatitis 
History of previous operations 
Description of scarring and infections (past, present) 
BUN, Blood urea nitrogen; FEV1, forced expiratory volume in 1 second; CBC, complete blood count; SGOT, serum glutamic oxylactic 
transaminase; SGPT, serum glutamic pyruvic transaminase. 
In addition, information will be obtained that will 
help to determine when the device should not be used 
or its use should be restricted to certain anatomic 
situations, and whether it should be considered for 
use in circumstances other than those provided by an 
unruptured infrarenal aortic aneurysm, such as anas- 
tomotic aneurysms, aortic aneurysms proximal to a 
previous aneurysm repair, ruptured aneurysms or 
infected aneurysms. 
Abdomina l  aort ic  aneurysm (infrarenal)  
w i th  iliac invo lvement  or  
aneurysm(s)  - b i furcated dev ices  
TPEG repair o f  these aneurysms will require a 
bifurcated or branched device, although it is pos- 
sible for some aortoiliac aneurysms to be repaired 
by a tubular TPEG device to revascularize one l imb 
supplemented by femorofemoral  bypass and occlu- 
sion of  the opposite common iliac artery by some 
means. (This type of  procedure is considered to 
be a subgroup o f  the aneurysms in the previous 
section.) 
In general the feasibility testing, the preproce- 
dural, intraprocedural, early postprocedural, mid- 
term postprocedural, and late postprocedural data, 
and the design of  comparative performance clinical 
trials will be similar to those outl ined in the previous 
section addressing tubular devices for abdominal 
aortic aneurysms. The use of  a bifurcated evice may 
be more complicated and possess pecific additional 
risks during device insertion and in the postproce- 
dural period. With bifurcated devices specific infor- 
mation regarding the status and maintenance of  
perfusion in the internal and the external iliac arteries 
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should be recorded before and at the various intervals 
after device insertion. Information regarding possible 
continued flow into the aneurysm from the internal 
iliac arteries and the status of the colonic circulation 
after the procedure should also be obtained. 
Peripheral aneurysm (femoral, popliteal, 
and others q in comparably sized 
arteries)-tubular devices 
In general, TPEG devices used to treat these 
lesions will have an expanded internal diameter f om 
6 to 16 ram. One possible design will have an 
attachment device at both ends, although in others a 
graft will be attached at one end with an endolumi- 
nally placed device, and arterial continuity will be 
established atthe other end by performing an open 
suture anastomosis. Other effective designs, such as 
grafts upported throughout their entire length, may 
also be developed. 
Feasibility testing with these devices will be per- 
formed on patients who have indications for opera- 
five repair and who satisfy the general requirements 
for feasibility testing already outlined. These feasibil- 
ity tests for aneurysms in these specific locations r 
should be carried out in at least 10patients monitored 
for 6 months to demonstrate r asonable safety and 
efficacy with regard to the primary criteria specified in 
Table I. Adequate preprocedural data should be 
collected to characterize the aneurysm, the distal 
circulation (ABI), and the patients' ystemic and local 
risk factors (Table 111). 
Intraprocedural, early, and early midterm postproce- 
dural data should include a description of the 
experimental device, the diameter and length of its 
components, a description of the placement proce- 
dure including the route of access, the anesthesia,  
description of the insertion procedure, the location of 
the device and its components (supplement with 
diagram), any procedural complications or mishaps, 
the need to perform any surgical or interventional 
reparative procedure to deal with problems that were 
encountered, blood loss, and length of hospital stay. 
qThese include isolated lilac, subclavian, and carotid artery 
aneurysms inpatients with appropriate proximal and distal arterial 
anatomy for device fixation. 
rIt may also be possible to combine results of a given device used 
for similar lesions in several different locations to demonstrate 
feasibility with smaller numbers of device implantations. In such 
combined feasibility studies, data will have to be stratified by 
location and emphasis hould be placed on the "worst case" or 
most difficult location to access and treat. Similar considerations 
may also apply to comparative performance t sting of devices for 
treating peripheral aneurysms in these locations. 
Data collected at 6 months hould include repetition 
of preprocedural studies that are required to demon- 
strate xclusion of the aneurysm from the circulation 
and maintenance of luminal continuity and distal 
arterial circulation without device migration, leakage, 
or other defects. These data should include ABI, 
duplex ultrasonography or CT scanning, MRI, or 
arteriography. 
Satisfactory completion of feasibility testing 
should be followed by comparative p rformance t sting. 
Data similar to that for the feasibility testing should 
be collected. Postprocedural data collection should 
take place at 3, 6, 12, 18, and 24 months. TPEG 
devices proposed for femoral aneurysms or other 
peripheral aneurysms hould be compared with 
standard prosthetic (PTFE or polyester fabric) or 
autologous grafts where appropriate. Several coop- 
erating centers may be required to accumulate a 
sufficient group of patients to enable a statistically 
and scientifically valid judgment to be made regard- 
ing safety and efficacy (as described earlier) and 
effectiveness (i.e., prevention of embolization, limb 
loss, and aneurysm rupture) for at least 1 year. 
If the comparative performance trials demon- 
strate that the TPEG performs as well as or better 
than operatively placed grafts, the manufacturer may 
seek clearance to market and sell the device. How- 
ever, the patients from the initial study should be 
monitored until long-term (3 to 5 years) data are 
available. 
Traumatic arterial lesions (false aneurysms, 
arteriovenous fistulas, mural injuries) 
The TPEG devices for treatment ofthese injuries 
will generally have an expanded internal diameter of 
6 to 25 mm depending on the artery that is injured 
and will probably consist of a 2 to 6 era-long 
attachment device covered except for 5 to 10 mm at 
its ends by a tube of polyester fabric, expanded PTFE, 
or some other material, s These devices should be 
deployed to cover the defect in the arterial wall (false 
aneurysms or arteriovenous fi tulas) or to reinforce 
the arterial wall and fix intimal flaps (mural injuries). 
Initially these devices will probably only be used to 
treat arterial injuries less than 4 cm in length because 
it is likely that longer injuries will be associated with 
sufficient soft tissue damage and internal or external 
bleeding and that standard operative repair will be 
SThis is one example. Other possible designs may be developed, 
e.g., a stent-like material incorporated uniformly within a graft 
matrix or some other combination of fixation device and graft. 
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required. However, it is conceivable that longer 
injuries could be treated by TPEGs. 
After appropriate bench and animal testing for 
prosthetic grafts that might be used in comparable 
locations, human feasibility testing should be carried 
out in patients who would otherwise require a 
standard operative repair and whose conditions are 
stable enough to permit preprocedural angiographic 
definition of the vascular injury mad the distal arterial 
circulation. Ideally, separate f asibility studies hould 
be performed for injuries of the aorta and innominate 
artery, the iliac and common femoral arteries, the 
subclavian and axillary arteries, the superficial femoral 
and popliteal arteries, and the carotid and vertebral 
arteries. In each of these five arterial systems, t these 
feasibility studies should show that the device can 
safely be implanted in lOpatients and can maintain a
satisfactory epair of the lesion with preservation of
luminal continuity without distal embolization for at 
least 6 months. 
Preprocedural data should be collected to charac- 
terize the location and length of the arterial injury, the 
cause of the injury (blunt trauma, gunshot or knife 
wound, or iatrogenic or other injury), the nature of 
the injury, and associated injuries. Intraprocedural 
data should include the diameter and length of the 
graft and the attachment device, a description of the 
placement procedure, the route of access, whether the 
device was inserted percutaneously or by open 
operation, the location of the device and its compo- 
nents (supplement with diagram), any procedural 
complications or mishaps, the need to perform 
surgical or catheter-based corrective procedures, 
procedural blood loss, and length of hospital stay. 
Early and &month postprocedural data should be 
similar to those already described for other TPEG 
devices and should demonstrate luminal continuity, 
correction of the arterial defect, maintenance of the 
distal circulation and freedom from device migration, 
leakage, embolization, or aneurysm formation. 
Satisfactory completion of feasibility testing in 
each location or system should be followed by 
comparative p rformance t sting in each or a combina- 
tHowever, because these are uncommon lesions, it may be 
necessary to combine results of a given device used in several 
different locations to demonstrate feasibility with smaller numbers 
of device implantations. In such combined studies data will have 
to be stratified by location and emphasis must be placed on the 
%vorst case" or most difficult location to access and treat. Because 
they involve arteries upplying the brain, devices for use in the 
carotid and vertebral arteries should be evaluated separately. 
Similar considerations may apply to comparative performance 
testing of  devices for treating arterial trauma in these locations. 
tion of the major arterial systems described above, 
recognizing the limited number of suitable patients 
available for inclusion in these trials. Ideally in each of 
these systems, TPEG device repairs hould be char- 
acterized with regard to the criteria listed in Table I 
so that comparisons can be made with similar data for 
operative repair of similar lesions. The procedural 
and postprocedural data collected should be similar 
to those already described. 
If the TPEG device proves equivalent or superior 
to standard repair for 1 year, the manufacturer may 
seek clearance to market and sell the device for these 
specific indications. Although the increased simplic- 
ity and minimally invasive nature of treating trau- 
matic injuries of these arteries with nonautologous 
TPEGs is attractive, such treatment should be 
validated by patency studies extending at least to 5 
years. Therefore all patients in these studies hould 
continue to be evaluated every 6 months for 5 years 
with use of the same parameters already described. In 
this way, the long-term effectiveness, as well as the 
limitations and late complications of TPEGs can be 
determined. Particular attention should be directed 
toward the patency results of these short devices in 
small-diameter arteries uch as the superficial femoral 
and popliteal where the long-term patency of pros- 
thetic grafts may be poor. 
Distal aorta and lilac artery (common and 
external) occlusive disease 
TPEGs that will be used to treat hese lesions will 
probably have an expanded internal diameter f om 6 
to 20 mm and either an attachment device at both 
ends of a tubular graft or a proximal fixation system 
and a distal suture anastomosis, although other 
configurations may be developed. A distal suture 
anastomosis may be necessary if the anatomic situa- 
tion demands that the graft terminate at a point 
where two important patent artery branches origi- 
nate (e.g., the junction of the superficial and deep 
femoral arteries). The requirements for bench and 
animal testing for the grafts used in these devices 
should be similar to those required for standard grafts 
used in these locations. 2426 However, because the 
grafts will be placed within dilated or recanalized 
occluded arteries, it is possible that they may not need 
to have the same structural nd porosity specifications 
as standard bypasses, but evidence supporting the 
safety of modified or new grafts hould be presented. 
Feasibility testing of these devices should be 
performed on patients who have indications for 
operative repair but who may also have a major 
systemic or local contraindication to such an opera- 
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tion. Contraindications to standard operative bypass 
grafting include severe heart or lung disease or other 
systemic disorders that preclude general or major 
regional anesthesia or factors such as scarring or 
infection that would make an open arterial operation 
excessively difficult or dangerous. In addition, the 
lesions may be suitable for treatment by conventional 
percutaneous balloon angioplasty (PTA) with or 
without endoluminal stent placement depending on 
the length or complexity of the occlusive and stenotic 
process. These feasibility tests should be carried out 
in at least lOpatients who are monitored for 6 months 
to demonstrate r asonable safety and efficacy. Ad- 
equate preprocedural data should be collected to 
characterize the nature and extent of the patients' 
occlusive disease (arteriography), the status of the 
distal circulation (ABI, pulse volume recordings 
[PVR]), and the patients' systemic and local risk 
factors (Table III). Intraprocedural data should in- 
clude the diameter and length of the graft(s) and the 
attachment systems, a description of the placement 
procedure including the route of access and whether 
it was performed open or percutaneously, unilaterally 
or bilaterally, the location of the graft(s) and stent(s) 
within the arterial tree (supplemented with diagram), 
a description of any procedural complications and the 
catheter-directed or surgical techniques required to 
correct he problem, and the length of hospital stay. 
Postprocedural d ta to demonstrate 6-month safety and 
efficacy should include repetition of the preproce- 
dural studies (ABI, PVR, arteriography, and duplex 
scanning) to document graft patency, improved 
distal perfusion and freedom from leakage, collateral 
or branch occlusion, or device migration. These data 
may be supplemented, when necessary, by imaging 
studies such as plain radiography, CT scanning, 
MRI, and IVUS. 
Satisfactory completion of feasibility testing 
should be followed by comparative p rformance testing 
in which the new TPEG device is compared, with 
standard prosthetic bypass grafts (aortobifemoral, 
axillofemoral, iliofemoral, or femorofemoral) and 
against PTA alone or supplemented by stents. 
Because of the variability of the disease in the 
aortoiliac segment, hese will be complex studies to 
conduct. Many patients will have to be enrolled to 
eliminate or define confounding variables. It is likely 
that these studies will have many arms and will 
require multiple collaborating centers. 
In these studies, adequate data should be collected 
on risk factors, the degree ofischemia, nd the arterial 
disease, as well as the local factors enumerated 
previously to be sure that he test groups receiving the 
new TPEG treatment and the standard therapy 
groups arc well matched except for the treatment 
uscd. Follow-up and data accumulation (with the 
criteria outlined in Table I) on these patients hould 
determine 1-year esults and then be continued to 
determine long-term (3 to 5 years) safety, efficacy, 
effectiveness, and durability. In addition, these stud- 
ics might provide an assessment of the relative ffects 
of these new devices and standard treatments on the 
progression of atherosclerotic disease, and of how 
device complications and failures should best be 
managed. 
Femoropopliteal occlusive disease 
The TPEGs that will be used to treat hese lesions 
will most likely have an expanded internal diameter 
from 4 to 8 mm. They may have an attachment 
system at one or both ends of a tubular graft, 
although the distal end may not require such a 
system, and either the proximal or distal anastomosis 
may be performed in the standard open-sutured 
fashion, or a stentlike component may be incorpo- 
rated in a graft matrix. These devices may be 
inscrtable pcrcutaneously or via an opcn arteriotomy. 
The requirements for bench and animal testing are 
similar to those already described for iliac TPEG 
devices. 
Feasibility testing of these devices for femo- 
ropopliteal occlusive disease should be carried out on 
patients who have indications for operative vein or 
prosthetic bypass and who also may have a major 
contraindication to such an operation. In addition, 
the lesions may be suitable for a standard PTA by 
virtue of their length or complexity. Data collection 
before, during, and after the procedures up to 6 
months hould parallel those described in the "Distal 
Aorta and Iliac Artery (Common and External) 
Occlusive Disease" section and should be obtained on 
at least 10patients to demonstrate safety and efficacy 
of the device for that length of time. 
Satisfactory completion of feasibility testing can 
then be followed by comparativepcrformance testing as 
described above for lilac occlusive l sions.U Because of 
the multiple variables in risk factors, degree of 
ischemia, and arterial disease in this setting, adequate 
numbers of patients will have to be studied so that 
confounding variables can be eliminated. It is there- 
fore likely that these studies will also require multiple 
UTPEG results hould be compared with standard surgical vein and 
prosthetic bypasses and possibly with PTA and PTA with stents (if 
the latter are shown to be safe and effective) in groups of patients 
suitable for treatment with PTA with or without stents. 
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collaborating centers and will have several arms. One 
obvious study group would be patients who do not 
have a useable autologous vein so that the perfor- 
mance of a TPEG procedure can be compared with 
that of a standard prosthetic graft. Data collection 
should permit evaluation of safety, efficacy, effective- 
ness, and durability of the new device at 1 year and 
ultimately after 4 to 5 years, which should allow valid 
comparisons with the more traditional operative and 
balloon angioplasty procedures, as well as determi- 
nation of the precise indications and contraindica- 
tions for use of these TPEG devices. 
Descending thoracic aorta 
The TPEG devices that will be used to treat 
lesions in this location will have expanded external 
diameters up to 45 mm or more. They may be 
comprised of a single or multiple contiguous stents 
covered by a graft, two separate stents or attachment 
systems at each end of a tubular graft or have some 
other design. They may be used to treat acute or 
chronic aortic dissections, degenerative atheroscle- 
rotic aneurysms, traumatic or postoperative false 
aneurysms, ulcerating mural lesions, intramural he- 
matomas, and possibly other lesions. They will 
probably be inserted in a fashion similar to devices 
used to treat infrarenal aortic aneurysms. 
The requirements for bench and animal testing, as 
well as feasibility and comparative p rformance trials 
will be similar to those already described for abdomi- 
nal aortic aneurysm devices. However, because sev- 
eral pathologic processes will be treated 
in the thoracic aorta, it will probably not be feasi- 
ble to perform separate trials on each before market- 
ing approval for general clinical usage is requested. 
Imaging of thoracic lesions with transesophageal 
echo and with Doppler color-flow studies may be 
used to supplement the preprocedural and postpro- 
cedural evaluations recommended for abdominal 
aortic aneurysms. 28 Experience to date dictates that 
TPEG procedures on the thoracic aorta be performed 
in a procedural room in which the following tech- 
niques are available: general anesthesia with endo- 
bronchial intubation, pulmonary artery catheteriza- 
tion, and, in some instances, the equipment and staff 
to perform emergency operation with complete 
cardiopulmonary b pass. When the latter may be 
required, the participation of a cardiothoracic sur- 
geon is mandatory. 
TPEG REGISTRY RECOMMENDATIONS 
To maximize the knowledge gained from the 
widespread early experiences in the developing field 
of TPEGs, the data from all feasibility and compara- 
tive performance trials that are conducted should be 
collected, stored, and analyzed by a central databank 
or registry. Submission of all clinical trial data to such 
a registry should be mandatory and a requirement for 
obtaining marketing approval. Such a registry is 
being developed by the same Endovascular Graft 
Committee that wrote these guidelines. Additional 
information about this TPEG registry can be ob- 
tained from K. Wayne Johnston, MD, Toronto 
General Hospital, Toronto, Ontario, Canada. 
TRAINING REQUIREMENTS FOR USAGE 
OF TPEGS 
For initial clinical studies with each device, 
principal investigators will need to work with the 
manufacturer to develop appropriate training pro- 
grams for all investigators. The teams that will be 
involved in the use of a given TPEG device must 
include an experienced vascular surgeon (or cardio- 
thoracic surgeon for procedures on the thoracic 
aorta) and interventional radiologist, both of whom 
devote a major portion ( > 50%) of their activity to 
the management ofnoncardiac vascular disease, wThe 
training program must include adequate large animal 
experience (or mock circulatory model experience) to
ensure technical proficiency with the usage of the 
device being evaluated. Although it is recognized that 
good animal models for human aneurysmal nd 
occlusive disease do not exist, animal (or model) 
experience should be obtained by placing the device 
under fluoroscopic control in an anesthetized animal 
(or model) in arteries large enough to approximate 
those that will be encountered in human patients. 
When individuals or teams have had this initial 
animal or model experience and then implanted the 
TPEG device in at least hree patients with acceptable 
results, they may qualify as instructors for othcr 
individuals who desire to perform investigational 
procedures with the device in question. The indi- 
viduals or teams being qualified in this way must 
possess the full knowledge of vascular disease and all 
its treatment methods and the requisite surgical and 
catheter-guidcwire skills and expcrience, as already 
outlined. They must participate as assistants in at least 
three procedures that use the device and that are being 
wSeparate raining and credentialing guideline documents for indi- 
viduals who can perform vascular surgery and endovascular proce- 
dures have been prepared by various pecialty organizations. 18-23 
The general principles expressed in these documents should also 
apply to this guideline document. 
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carried out by the individual or group who are 
serving as instructors. These background and training 
requirements apply to individuals or teams at other 
centers wishing to join an ongoing comparative 
clinical testing protocol. 
REQUIREMENTS FOR FACILITIES IN 
WHICH TPEGSs WILL BE 
USED CLINICALLY 
Although it is probable that some of these devices 
may ultimately be suitable for safe and reliable 
percutaneous introduction, 4,5 experience to date in- 
dicates that open vascular operations are required or 
may be required as a part of many TPEG insertion 
procedures or to treat complications or adverse 
events that may occur .  1'615 Accordingly, it is manda- 
tory that facilities in which these procedures are per- 
formed be suitable for the performance ofopen arte- 
rial operations and catheter-directed fluoroscopically 
guided techniques with high-quality imaging. Such 
facilities can take one of two forms. A standard oper- 
ating room or comparable ocation may be equipped 
to perform open arterial operations, digital imaging 
fluoroscopy, and arteriography, and catheter-guide- 
wire manipulations at several evels of the arterial 
tree. There are a number of ceiling- and floor- 
mounted igital fluoroscopy/arteriography units and 
movable radiolucent operating tables that are ideally 
adapted to the performance ofthese procedures inan 
operating room setting. However, it is also possible 
to perform them adequately with an electrically oper- 
ated radiolucent movable operating table and C-arm 
portable digital imaging and fluoroscopy with hard 
copy and videotape recording capability and prefer- 
ably with last image hold and roadmapping. The 
procedural room should be equipped with conven- 
tional (525 line) or high-resolution (1000+ line) 
imaging chains capable of resolving at least 3.3 line 
pairs per mm in the 9-inch image intensifier. The 
image intensifier should have a high contrast ratio 
(20:1), provide manual collimation, and be of 
high conversion gain. The room should also be 
equipped with a power injector for adequate digital 
angiography. 
Alternatively, a standard arteriography suite 
equipped for digital imaging fluoroscopy and cath- 
eter-guidewire technologies can be modified to 
permit emergency sterile open operations according 
to standards of the Association of Operating Room 
Nurses. 33 For procedures in which devices will be 
placed in the abdominal or thoracic aorta or iliac 
or visceral arteries, patient safety considerations, and 
the possible need to deal with emergency compli- 
cations mandate that they be performed in a room 
that is fully equipped and staffed with appropriate 
nursing and anesthesia personnel so that major 
vascular operations can be performed safely and 
expeditiously if required. For thoracic aortic pro- 
cedures, perfusionists and equipment for instituting 
total cardiopulmonary b pass must also be imme- 
diately available. 
In the future, different combinations of various 
imaging modalities other than fluoroscopy may 
prove equally effective and safe for the deployment of
TPEGs and may be substituted for those described 
above to facilitate TPEG device insertion and evalua- 
tion in different treatment environments. 
RADIATION SAFETY REQUIREMENTS 
Federal regulations regarding maximum fluo- 
roscopic radiation exposure rates must be followed. 
If high-level control (HLC) fluoroscopy is used, 
activation of this mode must be accompanied by a 
continuous audible signal and the output of the 
x-ray tube in HLC fluoroscopy should be closely 
monitored and measured and should not exceed 20 
R/min. A cumulative monitor of fluoroscopy time 
should be present, and the time should be recorded 
for each patient. The procedure room should meet 
the radiation protection standards of the National 
Council on Radiation Protection, 3437 and the work- 
ers should have awareness of the safety standards 
of the International Commission of Radiation Pro- 
tection. All personnel within the room should wear 
lead aprons, and individual state regulations re- 
garding personnel dosimetry should be followed. 
Quality control charts should be maintained on the 
radiography equipment, and arrangements should 
be made for their routine maintenance. All quality 
control data should be reviewed by a medical 
physicist at least annually? 7 The procedural room 
should have a safe, electrical primary wiring system 
and proper electrical isolation of all equipment 
attached to the patient. With the addition of an- 
giographic equipment and the presence of catheters 
within the vascular system, there should be periodic 
inspection of the electrical system, which should 
have equipotential hardwired grounding. Electrical 
safety checks should be reviewed at least annually 
by a qualified medical physicist. 
MODIFICATIONS OF 
THESE GUIDELINES 
The developmental paths of TPEGs, the optimal 
technology, their ultimate value, the complications of
their insertion, their impact on various arterial disease 
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processes, and the various modifications that may be 
introduced are presently unknown. It is therefore 
probable that these guidelines will evolve and change 
to encompass new treatment developments. Accord- 
ingly, future modifications and refinements of this 
document should be made as needed by the Endo- 
vascular Graft Committee of the Joint Council of the 
Society for Vascular Surgery and the North American 
Chapter of the International Society for Cardiovas- 
cular Surgery and the Society of Cardiovascular nd 
Interventional Radiology. 
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